abstract |
The present application discloses a formulation comprising an antibody that binds to domain II of HER2 (e.g., Pertuzumab) and an antibody that binds DR5 (e.g., Apomab) Lt; RTI ID = 0.0 > monoclonal < / RTI > antibodies formulated in histidine-acetate buffer, but not histidine-acetate buffer. n n Histidine-acetate buffer, pertuzumab, apomab, HER2 antibody, DR5 antibody |